BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34244816)

  • 1. Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.
    McArdel SL; Dugast AS; Hoover ME; Bollampalli A; Hong E; Castano Z; Leonard SC; Pawar S; Mellen J; Muriuki K; McLaughlin DC; Bayhi N; Carpenter CL; Turka LA; Wickham TJ; Elloul S
    Cancer Immunol Immunother; 2021 Sep; 70(9):2701-2719. PubMed ID: 34244816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
    Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
    Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells.
    Phan MT; Lee SH; Kim SK; Cho D
    Methods Mol Biol; 2016; 1441():167-74. PubMed ID: 27177665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4
    Awad RM; De Vlaeminck Y; Meeus F; Ertveldt T; Zeven K; Ceuppens H; Goyvaerts C; Verdonck M; Salguero G; Raes G; Devoogdt N; Breckpot K
    Sci Rep; 2023 Nov; 13(1):18995. PubMed ID: 37923822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.
    Martinet O; Ermekova V; Qiao JQ; Sauter B; Mandeli J; Chen L; Chen SH
    J Natl Cancer Inst; 2000 Jun; 92(11):931-6. PubMed ID: 10841829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
    Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
    Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an antibody-ligand fusion protein scFvCD16A
    Li Y; Xie S; Chen M; Li H; Wang Y; Fan Y; An K; Wu Y; Xiao W
    Microb Cell Fact; 2023 Apr; 22(1):67. PubMed ID: 37041591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
    Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
    Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
    Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
    Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expansion of human natural killer cells ex vivo].
    Huang QS; Li Q; Huang Y; Shang P; Zhang MJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1167-9. PubMed ID: 19068202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
    Wen T; Bukczynski J; Watts TH
    J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.
    Zhang X; Luo M; Dastagir SR; Nixon M; Khamhoung A; Schmidt A; Lee A; Subbiah N; McLaughlin DC; Moore CL; Gribble M; Bayhi N; Amin V; Pepi R; Pawar S; Lyford TJ; Soman V; Mellen J; Carpenter CL; Turka LA; Wickham TJ; Chen TF
    Nat Commun; 2021 May; 12(1):2637. PubMed ID: 33976146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
    Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
    J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.
    Gong W; Xiao W; Qian L; Gong C; Hu M; Pan X; Ji M
    Cell Mol Immunol; 2010 Nov; 7(6):477-84. PubMed ID: 20871627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
    Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.
    Xiao R; Mansour AG; Huang W; Chrislip LA; Wilkins RK; Queen NJ; Youssef Y; Mao HC; Caligiuri MA; Cao L
    Mol Ther; 2019 May; 27(5):922-932. PubMed ID: 30833178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
    Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
    Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.